A novel multipotent sigma 1/M1 muscarinic activator for a comprehensive therapeutic strategy in Alzheimer’s disease March 26, 2014
Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer’s Clinical Trial March 19, 2014
Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig’s Disease) March 10, 2014
Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds February 26, 2014
Sigma-1 Receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases – Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases January 23, 2014
Anavex Agreement with the Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS January 13, 2014
The Anticipated Clinical Effect of the new Alzheimer drug ANAVEX 2-73 in a Calibrated Quantitative Systems Pharmacology Platform. December 11, 2013
